🇺🇸 FDA
Patent

US 11306144

B7-H4 antibodies and methods of use thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11306144 (B7-H4 antibodies and methods of use thereof) held by Five Prime Therapeutics, Inc. expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
45
CPC classes
A61K, A61K2039/505, A61K2039/507, A61P, A61P35/00